Antibody Drug Conjugates (ADCs) are innovative biopharmaceuticals gaining increasing attention over the last two decades. The concept of ADCs lead to new therapy approaches in numerous oncological indications as well in infectious diseases. Currently, around 60 CECs are in clinical trials indicating the expanding importance of this class of protein therapeutics.
Introduction
Antibody Drug Conjugates (ADCs) are innovative biopharmaceuticals gaining more and more attention over the last two decades. They consist of potent small molecular cytotoxic drugs, which are covalently bound to a recombinant monoclonal antibody (mAb), via synthetic linkers. The antibody part has a key role in selective target cell recognition, while the conjugated potent cytotoxic drug is responsible for the effective elimination of the target cells [1, 2] . This concept lead to new therapy approaches in numerous oncological [3] [4] [5] and infectious indications [6, 7] as well as for arthrosclerosis [8] , anti-inflammatory treatments [9] and immunosuppression [10] . Currently, more than 60 CECs are in clinical trials and this number is expected to increase in the future [11] [12] [13] .
The first generation ADC, namely gemtuzumab ozogamicin (Mylotarg ® ) was approved by the US Food and Drug Administration (FDA) in 2000. The acid-labile hydrazon linker of gemtuzumab ozogamicin was not stable enough in the circulatory system, which resulted in non-specific drug release and limited clinical benefits. Finally, the drug has been voluntarily withdrawn from the market in 2010. Second generation ADCs, brentuximab vedotin (Adcetris ® ) and trastuzumab emtansine (Kadcyla ® ) were commercialzed in 2011 and 2013, respectively. These are currently the only two ADCs approved by the FDA and European Medicines Agency (EMA). Brentuximab vedotin is a cysteine conjugated ADC, in which monomethyl auristatin E (MMAE) warheads are attached to a chimeric anti-CD30 IgG1 mAb via cathepsin cleavable linkers. In cysteine conjugated ADCs, reduced inter-chain disulfides are conjugated, which finally results in drug load distribution of 0-8 for IgG1 and 0-12 for IgG2 host mAbs. Trastuzumab emtansine is a lysine conjugated ADC which consists of a humanized anti-HER2 IgG1 and emtansine (DM-1) payloads conjugated via non-cleavable linkers.
Lysine is a prevalent amino acid present in mAb sequences. From 90 possible conjugation sites of trastuzumab, around 20 are highly solvent accessible and capable of conjugation. The resulting mixture of conjugated species is unprecedentedly heterogeneous and shows drug load distribution from 0 to 8. The conjugation process of second generation ADCs provides IgGs with an average drug to antibody ratio (DAR av ) of 4.0 for brentuximab vedotin and 3.5 for trastuzumab emtansine. Conjugation reaction has to be well controlled, since DAR av and drug load distribution influence efficacy, pharmacokinetics and stability of the final product. The desired DAR av for second generation ADCs is around 4. Lower DAR may not efficiently eliminate target cells, while higher DARs possess shorter half-life in circulatory system and tend to form aggregates more easily [4] . Third generation ADCs are based on engineered mAbs possessing conjugation sites at defined positions, enabling the production of more homogeneous pools of ADC payloads. Currently, more than 40 site specific conjugation technologies are available. Conjugation site engineering is often combined with alternative conjugation chemistries. At least 10 of third generation ADCs have reached clinical development yet [3] . Heterogeneity of ADCs may be due to each component of the product. Among variations related to the host mAb itself (i.e. amino acid clipping, chemical modifications, glycosylation, aggregation, etc.) and to its production process/storage (i.e. particulates, leachables, endotoxins, sterility, etc.), several other critical quality attributes (CQAs) that are more ADC specific have also to be assessed. These include DAR, drug distribution, conjugated impurities, free drug species and residual conjugation solvents [14] . Analytical techniques used for the characterization of mAbs [15, 16] can usually be also used for the analysis of ADCs [17] [18] [19] [20] [21] . Several review papers recently appeared on ADC characterization, involving the use of mass spectrometry [19, 20] and separation based techniques [17, 18] , showing their key role of these analytical methodologies in this field. Here, we wanted to exclusively focus on liquid chromatographic approaches for the analytical characterization of ADCs. Due to the limited number of marketed products, this review focuses mainly on second generation ADCs, namely brentuximab vedotin and trastuzumab emtansine. The inherent heterogeneity of the lysine conjugated trastuzumab emtansine significantly limits the chromatographic applications for its characterization. The discussion of the cysteine conjugated ADC brentuximab vedotin is more detailed.
The aim of this review is to provide a general overview on the possibilities and limitations of liquid chromatography for ADC characterization, to help practicing chromatographers in developing reliable separation methods. Basic theoretical concepts are illustrated, together with most recent results in chromatographic method development and applications. The review discusses hydrophobic interaction chromatography (HIC) for the characterization of drug load distribution (which measures the homogeneity of the ADC population) and DAR av under native conditions, reversed phase chromatography (or reverse phase, RPLC) for the determination of DAR av and process/storage related impurities, using denaturing conditions and finally, size exclusion chromatography (SEC) for the determination of ADC size variants (above all aggregates). Multidimensional chromatographic solutions were also critically discussed, and future perspectives in method development, particle technology and possible separation methods are provided.
Hydrophobic interaction chromatography (HIC)
HIC can be considered as a historical chromatographic technique for the purification and characterization of proteins. HIC separates sample components according to their relative hydrophobicity using mild conditions (e.g. physiological pH conditions, ambient mobile phase temperature and no or moderated amount of organic solvents) which help to preserve the native-like conformation of protein species. This is the main benefit of HIC compared to RPLC in which proteins are separated under harsh, denaturing conditions. In HIC, non-covalent protein complexes, like cysteine conjugated ADCs preserve their conformation and do not dissociate into subunits like in RPLC. HIC separates individually loaded variants, while maintaining their Y-shaped mAb-structure and thus enabling the evaluation of drug-load distribution and the calculation of DAR av . On the other hand, HIC is not sufficiently efficient to separate positional isomers at the protein level, and due to the high mobile phase salt concentration, MS hyphenation is rarely feasible.
Recent review papers detailed HIC method development and also showed some useful applications [22] [23] [24] . The goal of the present review was to summarize the main points of these works and complete them with most recent results. HIC starts with an injection of the samples into a buffered high-salt concentration mobile phase, which leads to the adsorption of proteins at the surface of a moderately apolar stationary phase. Due to the complex nature of protein surface interactions, the adsorption process is still not well understood. It may consist of several solute -mobile phase -stationary phase interactions [22, 25] . Elution starts with decreasing salt concentration (inverse salt gradient). The eluting mobile phase is a low ionic strength (10-50 mM) buffer containing few percent of organic modifier, such as isopropanol, ethanol, etc. to facilitate desorption and enhance recovery. Modern HIC stationary phases are made of porous as well as non-porous silica as well as polymer particles, which are either bonded with short alkyl (ethyl-hexyl) chains or modified by ether or alkylamide chemistries. The ligand density is low compared to RPLC stationary phases, which makes the surface of HIC particles less hydrophobic. Various column dimensions are available for analytical scale separations from 4.6 mm × 3.5 mm to 4.6 mm × 250 mm packed with particles of 2.5-10 m. It is worth mentioning that not all HIC materials adapted for mAbs will appropriately work for highly hydrophobic multiply conjugated DAR species [26] . In some cases, the high DAR species cannot be eluted from the most hydrophobic materials [26] . Upon selection of the stationary phase, salt type and salt concentration of the mobile phase have to be adjusted. The phase system approach considering hydrophobicity indexes enables the proper set of salt concentration for any kind of salts generally used under HIC conditions (e.g. 1.5 M (NH 4 ) 2 SO 4 , 3.3 M CH 3 COONa and 3.9 M NaCl provide roughly equivalent lyotropic strength on most HIC phases) [22, 26] . Based on our experience, the use of NaCl or CH 3 COONa is preferred, since (NH 4 ) 2 SO 4 may cause large baseline drift and the quality of CH 3 COONH 4 may change upon storage. Mobile phase temperature has to be kept mild (e.g. below 30 • C) and mobile phase pH should be as close as possible to the isoelectric point (pI) of the protein, but should not contribute to protein denaturation. Separation can further be optimized by systematically modifying mobile phase organic concentration [27, 28] and gradient time and shape [27, 29] . Mobile phase organic modifier can change selectivity and may influence recovery of highly loaded species and thus affect DAR determination [28] . Optimum organic modifier percentage can be set between 5 and 15% concentration, depending on the stationary phase and the salt system used and should therefore be optimized after selecting the phase system. Increasing gradient time usually enhances peak capacity and resolution. Cysteine conjugated ADCs species are homologous series of proteins showing non-equidistant elution pattern when using linear gradients. Recently, a non-linear gradient was proposed, which provided better peak spacing for the elution of brentuximab vedotin payloads [29] . In this work, a logarithmic type gradient was approached by only four multi-linear segments. Finally, better separation was achieved for high DAR species and the unconjugated host mAb (considered to be an impurity in ADC samples) showed higher signal to noise ratio, due to the peak compression of the steep starting gradient segment. Fig. 1 shows the corresponding elution profile of cysteine linked IgG1 DARs, when using linear and logarithmic gradients.
HIC is the method of choice when determining drug load distribution by liquid chromatography [30] . From drug load distribution, average DAR can easily be calculated (see Section 6), while information on drug load distribution is lost when separating loaded species under denaturing conditions. Drug load distribution and average DAR can also be evaluated and sample components can further be analyzed when using HIC as a 1st dimension in a multidimensional setup (see Section 5).
Reversed phase liquid chromatography
Because of its versatility, flexibility, robustness, efficiency and MS compatibility, reversed phase liquid chromatography (RPLC) is one of the dominant approaches used for the analysis of peptides and proteins [18, 31] . For the analysis of ADCs, RPLC is mostly used to determine isomeric distribution, conjugate heterogeneity (DAR), and for performing peptide mapping [32] [33] [34] . Most commonly, the DAR species of reduced cysteine-linked ADCs related to the heavy chain (H) or light chain (L) as (L0, L1. . . and H0, H1. . .) are separated and then the DAR av can be determined [35] . In addition to reduced ADC sample, RPLC can also be applied on the native ADC to separate L, H, HH, HL and HHL fragments (sub-units). This approach can be useful, as a second dimension separation of a HICxRPLC setup, prior to MS. On the other hand, RPLC can also be a useful tool to determine free drug residues, residual solvents or other preservatives of ADC formulations [36] [37] [38] [39] [40] . It is also often applied in comparability studies and stability testing, as a primary QC method.
In RPLC -similarly to HIC -, protein species elute from an apolar stationary phase based on their hydrophobicity. However, it is important to notice that the applied conditions are very different in the two modes. In HIC, mostly non-denaturing (mild) conditions are applied, while in RP, harsh conditions have to be used to get reasonable peak width/shape and to limit non-desired on-column adsorption of the ADC species [35, 41] . Furthermore to have at least 50% recovery for all ADC species from a modern silica-based wide pore stationary phase, the temperature should not be set below 75 • C [35] . The recovery is especially critical for the naked mAb as well as for mAb with two drugs in the hinge region, the conjugated light chain (L1) and different HHL species (HHL1 and HHL3). Temperature also enhances the diffusivity of large solutes and therefore improves the mass transfer process. Ion-pairing agent also needs to be added (typically 0.05 − 0.1% TFA) into the mobile phase to inhibit peak broadening and tailing of charged solutes such as mAbs and their fragments [42, 43] . Finally, to elute ADC species from an RP column, around 25-50% organic modifier (acetonitrile or methanol) is required depending on the type/class of ADC and stationary phase. Such amount of organic modifier strongly impacts the conformation of the ADC and can cause its denaturation [35] . Under such harsh RPLC conditions, the H and L chain fragments are not kept under their native conformation and are separated, while in HIC, the H and L chain fragments maintain the physiological-like Y-shape conformation of the antibody through electrostatic and hydrogen bond interactions. Therefore, HIC and RPLC provide complementary information on DAR species and positional isomers.
RPLC has primarily been used to determine the DAR av of several ADCs containing auristatin drugs conjugated to inter-chain cysteines on native and engineered antibodies [18, [32] [33] [34] [35] . Fig. 2 shows a representative RPLC chromatogram of reduced cysteine linked IgG1 type ADC and its schematic structure. When performing a generic linear gradient between 25 and 50% organic modifier, the elution order is typically L0, L1, H0, H1, H2 and H3. As shown in Fig. 2 , H1 and H2 species can contain three different positional isomers, therefore they always elute as several peaks. In addition, the expected variability of amino-acid sequence and number of post-translational modifications are significantly higher on the H fragment than on the L. Thus, due to the high resolution power of recent RP columns, the variants of different H species can be partially separated and H0, H1, H2 and H3 always elute in a group of partially resolved peaks. By using MS detection or combining RPLC with information obtained from orthogonal (complementary) modes (e.g. HIC or capillary electrophoresis-sodium dodecyl-sulphate, CE-SDS), the DAR distribution can also be determined from RPLC -not only the DAR av -however it may require sophisticated data treatment [44] .
Structural characterization of ADCs is very challenging at the intact or reduced (partially fragmented) levels, due to their heterogeneous nature, large molecular size and possible low abundances of individual modified residues, therefore peptide mapping (bottom-up approach) of both lysine and cysteine conjugates are of interest [45] [46] [47] [48] . Tryptic and Asp-N peptide mapping in combination with electrospray ionization time-of-flight mass spectrometry (ESI-TOF/MS) have been reported to determine the conjugation sites of lysine-modified huN901-DM1 [45] . The use of Lys-C peptide mapping for characterizing the payloads of brentuximab vedotin (Adcetris), has also been reported [46] . All of the loaded peptides were separated by RPLC with excellent resolution and could be identified by MS. Furthermore, it was demonstrated that the drug was preferentially linked to the heavy chain L15 peptide Cys220 site, when only one drug was bound to the H. However, when two drugs were linked to the H, they were preferentially bound to the heavy chain L16 peptide's Cys 226 and Cys229 sites [18, 46] . Peptide mapping was also performed on engineered cysteine conjugates [47] . Tryptic digested sample was analyzed on LC/MS/MS instrument to locate the conjugation sites of a THIOMABvc-MMAE conjugate [47] . Recently a nano-liquid chromatographic MS method was reported to analyze the conjugation sites of lysine conjugated trastuzumab emtansine [48] . Following digestion with chymotrypsin, a signature ion fingerprinting approach was applied to specifically determine lysine residues with DM1 conjugation, and developed a normalized peak area quantitation method to characterize the percentage of DM1-conjugated lysine. With this integrative approach, 38 lysine residues were identified with DM1 conjugation, among 90 possible sites. It was also found that a trastuzumab emtansine biosimilar exhibited a specific preference of DM1-conjugation for several lysine residues, and such preference was consistent among three production batches [48] .
Limited proteolysis (middle-up level of analysis) is an alternative approach to bottom-up or intact mAbs analysis, which consists in using partial digestion with specific proteases for subunit analysis of mAbs and related products. Papain, pepsin, KGB, Ide-S or Ide-Z enzymes cut the antibody in the hinge region and are routinely used for mAb analysis [49] . These digestions result in moderate size fragments of 25-100 kDa (Fc/2, Fc, Fab, F(ab')2) which possess better chromatographic properties than intact mAb or ADC, enabling a better separation of variants. The combination of Ide-S digestion and reduction has been successfully applied, and improved the identification of positional isomers [46] . Fig. 3 shows a RPLC chromatogram obtained after Ide-S digestion and reduction of brentuximab vedotin.
A RPLC method was also reported for free drug analysis without any prior sample preparation [36] . By using this method, free drug and its related species were successfully analyzed. RPLC has also been applied for the analysis of 4-desacetylvinblastine, calicheamicin and auristatins [37, [50] [51] [52] .
Residual solvents with UV chromophore group (such as DMF and DMSO), can also be monitored and quantified by RPLC [18] .
Mostly generic linear gradient using acetonitrile as co-solvent methods are used to determine the DAR AV of cysteine linked ADCs. However, it has recently been shown that ternary mobile phase composition (water-acetonitrile-methanol) can be interesting to change selectivity [35] . Systematic method development approach and retention models have also been reported and suggested. By using columns of 150 × 2.1 mm packed with very efficient widepore stationary phases (UHPLC), a 3D retention model (gradient steepness, temperature and ternary composition) and robust optimized method can be developed within 2-3 working days [35] . In addition to the 3D model, simplified 2D models can also be performed for fast method development, which took less than one day (4 or 6 experiments with one sample). Generic (platform) method development approach was found to be feasible. It also worth mentioning that by understanding the retention behavior of ADC peaks and working with UHPLC columns, the analysis time could be shortened into the 20 min range, while 60-70 min long separations were reported on conventional HPLC systems.
Size-exclusion chromatography
Size-exclusion chromatography (SEC) is a traditional technique widely used for protein characterization and quality control [53] . The main application of SEC is the quantitative determination of protein aggregates. Therapeutic protein aggregates ranging from dimer to visible particles have been recognized for their potential to elicit immune responses [18, 54, 55] . Because of these safety risks, the industry and regulatory authorities consider aggregation as a critical quality attribute [56] .
SEC separates proteins into three major species: high molecular weight species (HMWS), main peak (predominantly the monomeric form), and low molecular weight species (LMWS) [57] [58] [59] . In SEC, proteins (mAbs or ADCs species) are separated on the basis of their difference in hydrodynamic volume in the mobile phase by diffusion in and out of stagnant pores. Nondenaturing aqueous buffers (e.g. phosphate) of medium ionic strength (containing NaCl or KCl) are commonly applied to minimize nonspecific interactions with the stationary-phase surface [60, 61] . SEC separation should be performed in conditions as inert as possible. Recently, SEC columns packed with sub-3 m particles have been introduced, making possible to perform ultra-high performance size-exclusion (SE-UHPLC or UHP-SEC) separations within 5-10 min analysis time range [53, 59, 62] . UHP-SEC columns perform two or three times lower plate heights compared to conventional 5-10 m SEC packing. Despite these advantages in terms of analysis time and resolution, both high pressure and elevated temperature (shear forces and frictional heating due to low column permeability) can induce some non-desired on-column protein aggregation [63] . The average pore size and pore size distribution of the stationary phase impacts the separation of ADC aggregates and monomer. Generally, an average pore size between 150 and 300 Å is appropriate for ADC analysis [53] .
Most published methods for ADCs use the same SEC method, as the ones used for the parent mAb [17] . However, this methodwhen applied to ADCs -provide poor peak shape (large tailing) and incomplete resolution of aggregates from the monomeric conjugate [17] . Beside peak tailing, a shift in elution time and poor recovery are also often observed for ADC peaks compared to mAbs [64, 65] . These results suggest that the attached hydrophobic drugs lead to nonspecific interactions between the ADC and the stationary phase.
Addition of an organic modifier to the mobile phase (i.e. methanol, isopropanol, acetonitrile, propylene glycol or DMSO) has been successfully used to overcome non-desired hydrophobic interactions [17, 53, 59, 65] . Generally, less amount of protic solvent is required to properly decrease hydrophobic interactions compared to aprotic solvents, however it is often compound and stationary phase dependent. It is important to notice that viscous solvents (e.g. isopropanol) can drastically increase the column pressure and can lead to artifacts. Fig. 4 shows the impact of mobile phase acetonitrile content on the recovery and peak shape of trastuzumab emtansine in UHP-SEC.
When analyzing mAb related products in SEC, electrostatic interactions are also often observed. A systematic evaluation of the salt additives effect on measured amounts of mAbs and ADCs evidenced their major role in aggregation assessment [65] . As example, a significant change of aggregate level was observed with a mobile phase containing 100 mM sodium phosphate dibasic and 200 mM NaCl, while no aggregates were detected without NaCl in the mobile phase. Despite the absence of monomeric protein adsorption on the stationary phase, enhanced secondary electrostatic interactions were suspected with the dimeric forms, due to a higher total number of positive charges and a conformational state which could increase the accessibility of protonated amino acids residues to the resin [60] . In the meantime, higher amounts of aggregates were measured with potassium-based mobile phases vs. sodium-based ones. Therefore, potassium-based salts should be preferred over sodium salts, to reduce possible secondary interactions between the dimeric forms of mAbs/ADCs and SEC materials as well as to lower protein-salts interactions.
SEC has also been used in combination with MS for analyzing the composition of ADCs [66] . By using aqueous acetonitrile as mobile phase, SEC can be directly coupled to ESI-MS [66] . Using SEC coupled to a multi-angle light scattering (MALS) detector in conjunction with UV absorption and refractive index has also been reported as an alternative method for DAR determination [67] .
SEC is also used in multidimensional separations, mostly as nondenaturing first dimension as discussed in Section 5.
Finally, it is worth mentioning that state-of-the-art UHP-SEC columns of 150 × 4.6 mm (which become more popular) can only be operated on fully optimized UHPLC systems possessing very low extra-column volume and variance [68] . Indeed, significant loss in efficiency is expected not only with conventional HPLC systems, but also with not-optimized UHPLC systems too (due to the very low retention of the compounds, −1 < k < 0 and related small column peak variance). It may happen that the apparent efficiency of SEC columns packed with sub-2 m particles can be much lower than that of those packed with larger particles (3-5 m), when operating them on conventional HPLC systems.
Multidimensional separation
Multidimensional (2D) chromatography could be a powerful technique for ADC characterization, since it allows the hyphenation of non-compatible MS chromatographic methods (i.e. SEC or HIC as the first dimension) to MS via a suitable interface (involving the use of RPLC as desalting step in the second dimension) [69] . Three main approaches are available, namely (1) fully comprehensive approach, (2) heart-cutting approach and (3) off-line sample collection. In comprehensive 2D-LC mode, the complete effluent from the first column is transferred to the second column with a switching valve [70] . After data acquisition, the partial chromatograms of both dimensions are aligned. In heart-cutting 2D-LC, only selected parts of the first column's eluent are transferred to the second column. By cutting out a peak from the first dimension separation, it can be analyzed with different selectivity on the second column. The main benefit of an ideal comprehensive 2D-LC combination is that the total peak capacity becomes the product of the peak capacities observed in the two dimensions, if both methods are considered as orthogonal. Beside orthogonality, obviously the two selected modes should provide a "true" separation of the compounds of interest. Orthogonality is not always a sufficient criterion (peak spacing, elution window, peak capacity and analysis time should also be appropriate).
2D-LC applications in the field of ADC characterization include the evaluation of drug distribution, DAR, aggregation, free small molecule drug content and stability study of both the mAbs and cytotoxic small molecules [18] .
An on-line HIC x RPLC-MS method has recently been reported for the thorough characterization of brentuximab vedotin [71, 72] . The purpose was to get relevant information on both drug loaded profile and structural information on positional isomers of each DAR of the cysteine-linked commercial ADC. The 1 D HIC conditions were carefully optimized by replacing the usual salt (ammonium sulfate) employed in the mobile phase with ammonium acetate, to improve the solubility of the salt in the hydro-organic media of the second dimension. Adding a sufficient amount of salt to the sample before injection reduces the injection solvent strength, thereby allowing to increase the injected amount and hence sensitivity. In the 2 D RPLC separation, the gradient profile was bracketed by two water steps to prevent any salt precipitation at the injection and both high flow-rate and high temperature were used to maximize peak capacity. Using this methodology, the presence of odd DARs (1, 3 and 5) and their relative abundance was assessed [72] . Odd DARs were considered as degradation products of even DARs during storage [72] . In another recent study, a similar HIC-RP 2D-LC coupled with UV and MS detection method has been developed and used for rapid characterization of a cysteine-conjugated ADC [73] . Fig. 5 shows contour plots of HIC x RP chromatograms observed for brentuximab vedotin.
It has to be mentioned that the separation of native or partially digested lysine linked ADC species is impossible in unidimensional chromatography. Indeed, the very heterogeneous sample -due to the huge number of possible conjugations and their combinations -elutes in one poorly resolved and broad chromatographic band in RPLC, IEX or HIC, which contains several co-eluted variants. Those samples clearly necessitate 2D separations and MS detection. Therefore, a combination of multiple heart-cutting IEX-RPLC performed at the intact protein and sub-unit levels, and RP x RP performed at the peptide level (using high and low pH gradients) was used since it provides valuable information on the drug load and its distribution on the protein backbone via lysine linkages (ado-trastuzumab emtansine) [74] . This approach also allowed the assessment of drug conjugation sites. The study clearly shows that one dimensional LC (IEX or RPLC) is not sufficient for the characterization of such complex samples and moreover requires the combination of both protein and peptide level analysis. Fig. 6 shows the unidimensional RPLC and IEX chromatograms of parent trastuzumab and its lysine conjugation and their 2D peptide maps.
Similar 2D methods can also probably be applied (or at least can be a good starting point) for ADCs as for their parent mAbs [75] . However, up to now, only a limited number of applications have been published.
A SEC-RP method was developed for the analysis of free drug and related small molecule impurities from ADC sample, without any prior sample preparation [76] . The 1 D separation provided information about size variants (dimers, aggregates) of the ADC and also separates the small molecular species. The small molecule peak from the 1 D was trapped and further analyzed by RPLC. The developed method was applied for stability testing and pre-formulation studies. It was found that both temperature and pH impact the stability of ADC in terms of protein aggregation and small molecular degradation pathway. Another heart-cutting SEC-RP setup was used to analyze free drug levels and to address low recovery issues of the free drug, which was previously observed when using a protein precipitation sample preparation method. Low free linker drug recovery in spiked samples was caused by its reaction with the remaining reactive conjugation sites on the ADC. The benefits of the method are the following: it did not require sample preparation, multiple injections of the sample over time was feasible, it provided higher throughput compared to manual sample preparation [77] .
Mixed-mode SPE column coupled with RPLC-MS has also been used to sensitively quantify free drug related species in antibodyfluorophore conjugate (AFC) [78] . An on-line SPE with RPLC/MS/MS has also been applied to determine maytansinoid (DM1) in human serum [79] . Other 2D-LC methods employing IEX, RP and mixedmode columns were used to separate polysorbate species and degradation products in mAb formulations [80] .
Determination of drug load distribution and average DAR
One of the most important critical quality attribute of an ADC is the DAR av , since it determines the amount of cytotoxic drug that can be delivered to the target cells. This feature directly affects safety and efficacy and has to be determined by the simultaneous use of multiple orthogonal analytical strategies. DAR av can be determined by UV-vis spectroscopy [17] , mass spectrometry [19, 20] and chromatographic methods. Optical methods are simple but require that the drug and the mAb have different spectra. Using extinction coefficients of the drug and the mAb, the individual concentrations of the drug and mAb can be determined and DAR av can be calculated. Mass spectrometry is widely used for the determination of drug load distribution and DAR av for cysteine conjugates and is practically the only useful technique (including LC-MS peptide mapping [34, 45, 48] ) for the characterization of lysine conjugates. With the number of conjugated drugs, the hydrophobicity of ADC is significantly increased. This might influence ionization efficiency and affect drug load distribution and DAR av observed by MS. Recently, a study on site specific conjugation analysis of trastuzumab emtansine revealed differences in ionization efficiency for conjugated and unconjugated peptides [48] . A relative ionization intensity factor (RIIF) was determined from calibration curve slopes of conjugated and unconjugated peptides, which was then applied to correct raw conjugation ratios. Interestingly, in spite of obvious differences in ionization efficiency for loaded and naked peptides, final DAR av values determined by the above method and obtained from intact mass analysis were very close (3.1 and 3.2, respectively). Another option is the deconjugation of the drug from the host mAb and the determination of individual drug and mAb concentrations. In this case, efficiency of deconjugation has to be carefully assessed since incomplete reaction may lead to biased DAR av values [81] .
Drug load distribution can easily be evaluated from HIC chromatograms and DAR av can be calculated from the individual peak areas using the following equation [30] :
Where n is the number of loaded drug (DAR) corresponding to the HIC peak (mAb, D2, etc. corresponding to the host mAb, doubly loaded, etc. species) possessing an area of A n . A similar equation can be used in intact mass spectrometry, with replacing A n by the peak intensity. Under denaturing conditions, non-covalent cysteine conjugated ADCs dissociate in their heavy chains (H) and light chains (L). Reduction of remaining disulfides in moderately loaded species facilitates the complete dissociation of H and L, which can then be separated by RPLC and DAR av can be calculated using the following equation:
Where A n,L and A n,H are the peak areas of the individually loaded light chain (L and L1) and the heavy chain (H, H1, H2 and H3) species, respectively. Subunit specific analysis is of increasing importance in the characterization of mAbs and ADCs [82] , in which proteins are enzymatically fragmented to their (F(ab')2) and Fc fragments. These fragments can be further processed by chemical reduction of their disulfide bridges, to get Fd, Fc/2 and L fragments, which are more favorable for LC and MS analysis. Once the ADC is processed and analyzed under these conditions, DAR av can be determined from the peak areas of these fragments [83] :
Where A n,Fd are the peak areas of the individually loaded Fd species (Fd, Fd1, Fd2 and Fd3) . Fig. 7 . shows the chromatographic profiles and annotated peaks for the above DAR av calculations. The bottleneck of DAR av calculations from chromatographic peaks can be the incomplete recovery of loaded species under improperly set chromatographic conditions. In one of our recent study, we proved that the concentration of an organic mobile phase additive in HIC played a key role in correct DAR determination [28] . In another study in RPLC mode, mobile phase temperature was found to be critical for the adsorption of loaded sub-units [35] . Determination of DAR av is sometimes further complicated by the lack of resolution between the peaks to be evaluated. Resolution can usually be enhanced by increasing gradient time and column length [22, 84, 85] . It has however to be kept in mind that harsh mobile phase conditions (like strongly acidic pH or elevated temperature, which are typical of RPLC separations) might degrade samples leading to artifact peaks and biased evaluation [41] . Typical degradation products of brentuximab vedotin are odd DAR species which may be formed upon stress and/or improper storage conditions, leading to decreased DAR av and unwanted changes in therapeutic properties [72] .
Future perspectives

HILIC
Thanks to some recent developments in column technology, wide-pore phases are now commercially available for hydrophilic interaction chromatographic (HILIC) separations and makes possible the separation of hydrophilic variants of peptides, protein fragments and intact proteins [86] [87] [88] . HILIC has recently been applied to the qualitative comparison of the glycosylation profiles of originator and biosimilar mAb and ADC products. By evaluating the chromatographic profile of the HILIC middle-up analysis, it was possible to quickly assess the most abundant glycosylation moieties and to highlight the differences between originator and biosimilar products. HILIC can also be interesting for 2D separations (e.g. combined with RP). Up up to now only a very few wide-pore stationary phases are available.
HIC
Surprisingly, technological progresses in HIC are relatively slow. This is probably due to the fact, that this mode was historically applied to proteins purification purposes. Now, HIC becomes increasingly popular at the analytical scale, thanks to the strong developments of mAbs and ADCs, and therefore revolutionary progress in HIC column technology is expected in a close future [22] . Applying columns packed with sub-2 m and sub-3 m particles can open a new level of performance in HIC. Using superficially porous particles (SPP) instead of fully porous ones could further improve the efficiency of HIC separations. There is also a lack of narrow bore columns, since 4.6 mm i.d. columns remain the gold standard today. 2.1 mm i.d. HIC columns could indeed drastically shorten analysis time, improve throughput and reduce sample consumption.
Off-line HIC -native MS has been applied for the characterization of brentuximab vedotin [89] . HIC fractions were collected, desalted and analyzed by ion mobility spectrometry (IMS) and native MS, assessing the interpretation of each HIC peak.
Online HIC-MS could also make sense. A recent study proposed a new series of more-hydrophobic HIC stationary phases allowing to retain proteins with MS-compatible mobile phases [90] . These new HIC materials appeared to work as a hybrid form of conventional HIC and RP chromatography (more hydrophobic than common HIC phases). Online HIC-MS was successfully applied for both qualitative and quantitative analysis [90] .
SEC
A smart idea of analysis time reduction is to use two SEC columns in parallel [91, 92] . A significant reduction of analysis time can indeed be obtained by combining interlaced sample injections with parallelization of two narrow bore columns packed with sub-2 m particles. With this strategy, both lag times before and after the peaks of interest can be eliminated, resulting in an assay time below 2 min [91] . A further increase in throughput can be achieved when applying interlaced injections on two columns operating in parallel. Compared to interlaced chromatography, the assay time in parallel interlaced SEC is further reduced. Two switching valves need to be used to direct the flow alternately between the autosampler, the two columns and the detector. This methodology has been successfully applied to analyse mAb aggregates.
To improve the sensitivity of aggregate determination or handle very small amounts of available samples, the use of capillary columns in SEC appears to be a promising approach. However, several key modifications to a commercially available liquid chromatography system are required to reduce the system volume and associated extra-column band broadening, which could be critical for capillary SEC operation. Despite this limitation, 300 mm x 300 m i.d. SEC capillary columns were however applied for the separation of mAbs fragments [93, 94] .
Very recently SPPs have been successfully applied in SEC [95, 96] . At first sight, the low pore volume of SPPs is thermodynamically disadvantageous, but the loss of pore volume can be compensated by shortening the diffusion length of the solutes inside the pores. Obviously, it results in a limited elution window but can enhance the separation efficiency in some cases.
IEX
Ion exchange chromatography is widely used for mAb characterization, especially for the separation of acidic and basic variants, related to post-translational modifications [97] . Salt and pH gradients are often applied in cation-exchange mode for intact and partially digested mAbs. However, depending on the changes in the chemical and physical characteristics of an antibody upon conjugation with a small molecule drug and the conjugation site, methods that can be applied to the parent antibody may not be applicable to the ADC [18] . Conventional IEX is indeed not adapted to cysteine conjugated ADCs, as the presence of linked cytotoxic drugs increases the hydrophobicity and may not change the net charge of the antibody relative to unconjugated antibodies. This may results in poor separation quality under IEX conditions.
On the contrary, the attachment of an uncharged linker and drug through lysine residues decreases the net positive charge by one for each bound drug-linker. In this case, separation based on charge, such as using IEX, results in profiles that characterize the drug load, rather than proving information about the underlying mAb [98] . There are only a few published reports of charge-based assays applied to ADCs. For gemtuzumab ozogamicin, the IEX profile showed that most of calicheamicin was on approximately half of the antibody while 45-65% of the product was a low conjugated fraction, essentially unconjugated antibody [ 99, 100] . Multiple charge variant peaks were observed during CEX analysis of several different thiomabs [100] . In another study, the effects of chemical conjugation on the electrostatic properties of Fc-conjugates were estimated [101] . Probably IEX can be interesting in 2D setups as the first dimension in combination with an MS compatible mode in the second dimension (RP, HILIC). For mAbs, comprehensive IEX x RPLC coupled with TOF/MS has already successfully been applied [102] .
Conclusion
Currently there are two second generation ADCs on the market, the cysteine conjugated brentuximab vedotin and the lysine conjugated trastuzumab emtansine. Around 60 CECs are under clinical development including 10 in late stages showing the potential of ADC based therapies. The complexity of these promising therapeutics address new challenges to analysts. Among other analytical techniques liquid chromatographic approaches play a very important role in the characterization of ADCs.
Hydrophobic interaction chromatography (HIC) regains a large interest for the analysis of ADCs. Recent achievements in method development strategies involving quality by design based approaches and the availability of various analytical HIC columns may further expand its applications. HIC was successfully used in two dimensional HIC x RPLC-MS setup. In this way, both evaluation of drug load distribution and MS assignation of separated positional isomers can be performed in a single experiment. Further progress in column technology is expected with the introduction of sub-2 and sub-3 m particles, core-shell particle morphology and narrow bore (2.1 mm i.d.) columns to shorten analysis time and increase throughput.
Reversed phase chromatography (RPLC) is a well-established and benchmark separation technique due to its versatility, flexibility, robustness, efficiency and MS compatibility. It is frequently applied in structure elucidation, comparability studies and stability testing as a primary QC method. Software supported method development is fast and fits to regulatory requirements. Nevertheless, it brings deeper understanding of chromatographic behaviour of protein species, which helps to significantly decrease analysis time. Very efficient, wide-pore stationary phases with various chemistries and column dimensions are available from most of the vendors making column interchangeability easily affordable. RPLC is adapted both for first and second dimensions in 2D setups, enlarging the chromatographic space by the use of orthogonal methods for complex samples. RPLC in the second dimension makes possible to couple MS with inherently non-MS-compatible modes (e.g. HIC, SEC, IEX).
Size-exclusion chromatography (SEC) is a traditional technique, which is widely used for protein characterization and quality control. Recent sub-3 m SEC particles made possible to perform ultra-high performance (pressure) size-exclusion (SE-UHPLC or UHP-SEC) separations within 5-10 min analysis time range. On the other hand, pressure and temperature should be kept in a reasonable range to avoid on-column aggregation. In spite of the inertness of modern SEC materials, ADCs may show tailed peaks and recovery of HMWS might be critical due to secondary interactions. For this reason, mobile phase should be carefully optimized in terms of salt and organic modifier type and their concentration. SEC x RPLC setup enables the analysis of free drug and related small molecule impurities from ADC sample without any sample preparation.
Probably the most interesting perspective in liquid chromatographic characterization of ADCs is the use hydrophilic interaction chromatography (HILIC). Thanks to recent developments in column technology, now wide-pore phases are commercially available and make possible the separation of hydrophilic variants of peptides, protein fragments and intact proteins. HILIC has recently been applied for the qualitative evaluation of the glycosylation profiles of mAb and ADC products and can also be interesting for 2D separations.
Due to intensive development in particle, column and instrument design, liquid chromatography finds its applications from time to time and makes feasible characterization of highly complex samples such as ADCs. Analysis of novel biotherapeutics e.g. bispecific antibodies, fusion proteins, antibody-biologic conjugates, etc. may address new challenges which are expected to overcome by the help of existing technologies and future innovations in liquid chromatography.
